key articles
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
Friday, 8 August 2008 - In an open-label, multicenter, dose-escalation study Higano et al. (2008) evaluated multiple dose levels of immunotherapy in patients with metastatic hormone-refractory prostate cancer (HRPC).
The...
Authors: Higano et al.
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy
Friday, 8 August 2008 - Following a study employed vaccine, the hormone nilutamide, and the combined therapy (crossover for each arm) with an endpoint of time to progression, Madan et al. (2008) reported survival analysis at 6.5...
Authors: Mdan et al.
Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature
Friday, 8 August 2008 - Accurate estimates of risk are essential for physicians if they recommend a specific management to patients with prostate cancer. Accurate risk estimates are also required for clinical trial design, to...
Authors: Shariat et al.
Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia
Thursday, 7 August 2008 - Neuhouser et al. (2008) investigated whether peptides involved in cellular proliferation and apoptosis, [insulin-like growth factor I (IGFI) and its major binding protein (insulin-like growth factor...
Authors: Neuhouser et al.
Phase II study of fulvestrant (faslodex®) in castration resistant prostate cancer
Thursday, 7 August 2008 - Preclinical evidence supports the role of estrogen receptor signaling in prostate cancer. Chadha et al. (2008) investigated the tolerability and efficacy of fulvestrant, a pure estrogen receptor...
Authors: Chadha et al.
Survival following primary androgen deprivation therapy among men with localized prostate cancer
Wednesday, 6 August 2008 - Despite a lack of data, increasing numbers of patients are receiving primary androgen deprivation therapy (PADT) as an alternative to surgery, radiation, or conservative management for the treatment of...
Authors: Lu-Yao et al.
Robotic laparoscopic radical prostatectomy for biopsy Gleason 8 to 10
Wednesday, 6 August 2008 - Shikanov et al. (2008) evaluated the pathologic results and postoperative outcomes for men undergoing robot-assisted laparoscopic radical prostatectomy (RLRP) for biopsy Gleason score (GS) 8 to 10...
Authors: Shikanov et al.
Laparoscopic port-site metastasis in urologic surgery
Tuesday, 5 August 2008 - Port-site metastasis has been an increasing concern with the spread of laparoscopy in managing urologic malignancies. Eng et al. (2008) reviewed port-site metastases reported in the urologic oncology...
Authors: Eng et al.
Impact of obesity on clinicopathologic outcomes after robot-assisted laparoscopic prostatectomy
Tuesday, 5 August 2008 - Boorjian et al. (2008) investigated the impact of body mass index (BMI) on pathologic and functional outcomes after robot-assisted laparoscopic prostatectomy (RALP).
The authors evaluated 400 consecutive...
Authors: Boorjian et al.
A new fiducial marker for image guided radio therapy of prostate cancer
Monday, 4 August 2008 - A new fiducial marker for image guided radiotherapy (IGRT) based on a removable prostate stent made of Ni Ti has been developed during two previous clinical feasibility studies. Carl et al. (2008)...
Authors: Carl et al.
